Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Roberto Carcereri De Prati"'
Autor:
Mohamed‐Eslam F. Mohamed, Yuli Qian, Ronilda D'Cunha, Teresa Sligh, Laura K. Ferris, Ann Eldred, Gweneth F. Levy, Shuai Hao, Shashikanth Gannu, David G. Rizzo, Wei Liu, Sasha Jazayeri, Howard Sofen, Roberto Carcereri De Prati
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 1, Pp n/a-n/a (2024)
Abstract Cedirogant is an inverse agonist of retinoic acid‐related orphan receptor gamma thymus (RORγt) developed for the treatment of moderate to severe chronic plaque psoriasis. Here, we report the results from two phase I studies in which the p
Externí odkaz:
https://doaj.org/article/e6092a073daa4e0988785d2ccda67ab3
Autor:
John F. Bohnsack, John R. Medich, Melissa J. McIlraith, Steven N. Goodman, Alberto Martini, Ivan Foeldvari, Richard Mouy, Valeria Gerloni, L. Wagner Weiner, Andreas Reiff, Kirsten Minden, Christy Sandborg, Richard K. Vehe, Dana Nemcova, Nicolino Ruperto, Lawrence Jung, Hans Iko Huppertz, Katerina Jarosova, Edward H. Giannini, Nancy Y. Olson, Roberto Carcereri-De-Prati, Dirk Elewaut, Gerd Horneff, Daniel J. Lovell, Jozef Rovensky
Publikováno v:
New England Journal of Medicine. 359:810-820
Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis.Pa
Autor:
Martin Rudwaleit, Sonja Kary, Martina Kron, Hartmut Kupper, Eduardo Loza Cortina, Joachim Sieper, Pascal Claudepierre, Roberto Carcereri-De-Prati, Paul Wordsworth
Publikováno v:
The Journal of rheumatology. 36(4)
Objective.We evaluated the effectiveness and safety of adalimumab in a large cohort of patients with active ankylosing spondylitis (AS) and identified clinical predictors of good clinical response.Methods.Patients with active AS [Bath AS Disease Acti